ReviewEuropean archives of psychiatry and clinical neuroscience2008
Do SSRIs or antidepressants in general increase suicidality? WPA Section on Pharmacopsychiatry: consensus statement.
Review in European archives of psychiatry and clinical neuroscience, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 89 citations in OpenAlex.
- Is the Chinese medicinal formula Guipi Decoction () effective as an adjunctive treatment for depression? A meta-analysis of randomized controlled trials.Chinese journal of integrative medicine · 2017Pooled it
- Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2009Pooled it
- Adding cognitive therapy to antidepressant medications decreases suicidal ideation.Journal of affective disorders · 2021Trial
- A novel probiotic formula, BLLL, ameliorates chronic stress-induced depression-like behaviors in mice by reducing neuroinflammation and increasing neurotrophic factors.Frontiers in pharmacology · 2024Article
- Intranasal Monophosphoryl Lipid a Administration Ameliorates depression-like Behavior in Chronically Stressed Mice Through Stimulation of Microglia.Neurochemical research · 2023Article
- The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries.European archives of psychiatry and clinical neuroscience · 2022Article
- Suicidal Ideation and Suicidal Behavior as Rare Adverse Events of Antidepressant Medication: Current Report from the AMSP Multicenter Drug Safety Surveillance Project.The international journal of neuropsychopharmacology · 2018Article
- Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD).The international journal of neuropsychopharmacology · 2018Article
- Suicide in stroke survivors: epidemiology and prevention.Drugs & aging · 2015Review
- Depression in cancer patients.EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.] · 2013Review
- A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdose.Therapeutic advances in psychopharmacology · 2013Article
- Antidepressant Utilization and Suicide in Europe: An Ecological Multi-National Study.PloS one · 2013Article
- Loudness dependence of auditory evoked potentials (LDAEP) in clinical monitoring of suicidal patients with major depression: a pilot study.European archives of psychiatry and clinical neuroscience · 2012Article
- Achievement and maintenance of the new impact factor 2010.European archives of psychiatry and clinical neuroscience · 2011Article
- Evidence-based pharmacotherapy for pediatric obsessive-compulsive disorder and chronic tic disorders.Journal of central nervous system disease · 2011Article
- Antidepressants and Suicide Risk: A Comprehensive Overview.Pharmaceuticals (Basel, Switzerland) · 2010Review
- Seasonality of suicide attempts: association with gender.European archives of psychiatry and clinical neuroscience · 2010Article
- Antidepressant-induced suicidality: an update.CNS neuroscience & therapeutics · 2010Review
- Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations.European archives of psychiatry and clinical neuroscience · 2010Article
- Achieving adolescent adherence to treatment of major depression.Adolescent health, medicine and therapeutics · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the past few years several papers have reported critically on the risk of suicidal thoughts and behaviour associated with antidepressants, primarily SSRIs. The risk-benefit ratio of antidepressant (AD) treatment has been questioned especially in children and adolescents. The critical publications led to warnings being issued by regulatory authorities such as the FDA, MHRA and EMEA and stimulated new research activity in this field. However, potential harmful effects of antidepressants on suicidality are difficult to investigate in empirical studies because these have several methodological limitations. Randomised controlled trials (RCTs) are the most reliable way to test the hypothesis that AD have such side effects. In addition to meta-analyses of RCTs, complementary research methods should be applied to obtain the most comprehensive information. We undertook a comprehensive review of publications related to the topics ADs, suicide, suicidality, suicidal behaviour and aggression. Based on this comprehensive review we conclude that ADs, including SSRIs, carry a small risk of inducing suicidal thoughts and suicide attempts, in age groups below 25 years, the risk reducing further at the age of about 30-40 years. This risk has to be balanced against the well-known beneficial effects of ADs on depressive and other symptoms (anxiety, panic, obsessive-compulsive symptoms), including suicidality and suicidal behaviour. According to the principles of good clinical practice, decision making should consider carefully the beneficial effects of AD treatment as well as potentially harmful effects and attempt to keep the potential risks of AD treatment to a minimum. It is the major problem facing efforts to identify the possible 'suicidal effects' of antidepressants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.